Review article: metoclopramide and tardive dyskinesia

Background  Metoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In 2009, the FDA issued a black box warning regarding long‐term or high‐dose use of this medication because of the risk of developing tardive dyskinesia.

[1]  A. McCall,et al.  The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. , 1993, Archives of internal medicine.

[2]  Sebastian Schneeweiss,et al.  Managing drug-risk information--what to do with all those new numbers. , 2009, The New England journal of medicine.

[3]  D. Jeste,et al.  Metoclopramide and Tardive Dyskinesia , 1994, Biological Psychiatry.

[4]  C. Gerfen,et al.  A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Lieberman,et al.  Diabetes and development of tardive dyskinesia. , 1993, The American journal of psychiatry.

[6]  C. Pamer,et al.  Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. , 2004, Journal of the American Pharmacists Association : JAPhA.

[7]  A. G. Fernández,et al.  Peripheral receptor populations involved in the regulation of gastrointestinal motility and the pharmacological actions of metoclopramide-like drugs. , 1985, Life sciences.

[8]  D. Jeste,et al.  Gender differences in tardive dyskinesia: a critical review of the literature. , 1992, Schizophrenia bulletin.

[9]  R. McCallum,et al.  Domperidone: Review of Pharmacology and Clinical Applications in Gastroenterology , 2007, The American Journal of Gastroenterology.

[10]  Anthony Davidson,et al.  Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia , 2008, Journal of clinical pharmacology.

[11]  Hye-Kyung Jung,et al.  Incidence , Prevalence , and Outcomes of Patients With Gastroparesis n Olmsted County , Minnesota , From 1996 to 2006 , 2022 .

[12]  D. Jeste,et al.  Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases. , 1992, Archives of family medicine.

[13]  D. Flockhart,et al.  Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[14]  A. Taburet,et al.  Pharmacokinetics of metoclopramide in patients with liver cirrhosis. , 1991, British journal of clinical pharmacology.

[15]  R. Fisher,et al.  American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. , 2004, Gastroenterology.

[16]  E. Melamed,et al.  Tardive Dyskinesia Associated with Metoclopramide , 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[17]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[18]  J. Os,et al.  Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: A meta analysis , 2006, Schizophrenia Research.

[19]  R. McCallum,et al.  Metoclopramide: pharmacology and clinical application. , 1983, Annals of internal medicine.

[20]  G. Corazza,et al.  Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics , 2004, Alimentary pharmacology & therapeutics.

[21]  M. Rawlins,et al.  Extrapyramidal reactions with metoclopramide. , 1985, British medical journal.

[22]  J. Jankovic,et al.  Drug Insight: from disturbed motility to disordered movement—a review of the clinical benefits and medicolegal risks of metoclopramide , 2006, Nature Clinical Practice Gastroenterology &Hepatology.

[23]  C. Gerfen.  Molecular effects of dopamine on striatal-projection pathways , 2000, Trends in Neurosciences.

[24]  S. Sarna,et al.  Gastrointestinal motor correlates of vomiting in the dog: quantification and characterization as an independent phenomenon. , 1986, Gastroenterology.

[25]  N. Yoshida,et al.  The broad‐spectrum anti‐emetic activity of AS‐8112, a novel dopamine D2, D3 and 5‐HT3 receptors antagonist , 2001, British journal of pharmacology.

[26]  P. Pasricha,et al.  Treatment of gastroparesis: a multidisciplinary clinical review , 2006, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[27]  P. Jolliet,et al.  Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. , 2007, Pharmacological research.

[28]  A. Lembo,et al.  Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. , 2009, Gastroenterology.

[29]  P. Blain,et al.  The pharmacokinetics of single doses of metoclopramide in renal failure , 2004, European Journal of Clinical Pharmacology.

[30]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[31]  Jane S. Paulsen,et al.  Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. , 1995, Archives of general psychiatry.

[32]  Zeruesenay Desta,et al.  The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[33]  D N Bateman,et al.  Clinical Pharmacokinetics of Metoclopramide , 1983, Clinical pharmacokinetics.

[34]  T. Shinkai,et al.  Clinical implications of pharmacogenomics for tardive dyskinesia , 2004, The Pharmacogenomics Journal.

[35]  M. P. Turpin,et al.  Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. , 1996, Biochemical and biophysical research communications.

[36]  C. Dooley,et al.  Dopamine antagonists in the upper gastrointestinal tract. , 1984, Scandinavian journal of gastroenterology. Supplement.